Open Actively Recruiting

RA-PRO PRAGMATIC TRIAL

About

Brief Summary

The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another TNFi-biologic, i.e., a second TNFi-biologic first. This is not based on solid evidence, but on arbitrary algorithms often proposed by health insurance plans, and/or physician experience and habit (TNFis launched 22 yrs ago vs. the first tsDMARD 8 years ago vs. first non-TNF-biologic launched 17 years ago). This study will fill a critical knowledge gap by generating CER data for important PROs between these treatment options, switching to a non-TNFi biologic or a tsDMARD in patients with active RA despite the use of a TNFi-biologic.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 3

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

  • Patients with active, disabling RA (CDAI ≥10 and HAQ ≥0.5) despite the use/experience of a TNFi-biologic OR discontinued the medication(s) due to intolerability or toxicity irrespective of treatment duration prior to the first dose of study drug ;
  • If receiving glucocorticoids (≤10 mg/day of prednisone of equivalent) or NSAIDs, on stable doses for ≥2 weeks prior to randomization; and
  • Insurance plan or patient assistance program allows access to at least 1 drug in each of the two treatment strategies, TNFi-biologic vs. tsDMARD. Participants will be allowed to continue their conventional synthetic DMARD (csDMARD) therapy if they had been using it for ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, and leflunomide (TNFi-biologic and tsDMARD) through insurance plan or a patient assistance program/plan.

Exclusion Criteria:

  • Prior treatment with more than three biologics, defined as TNFi-biologic or non-TNFi biologic
  • Prior treatment with targeted synthetic DMARD
  • Concomitant use of leflunomide, sulfasalazine, cyclosporine, or azathioprine within 2-months before randomization;
  • History of sensitivity to all 4 non-TNF-biologic or a targeted synthetic DMARD;
  • Glucocorticoid injection (intravenous, intramuscular, or intraarticular) within 1 month of study entry;
  • Live vaccine within 90 days of study entry;
  • Acute or chronic infections with parenteral antibiotics or hospitalization (including tuberculosis, bacterial sepsis; invasive fungal infections (such as histoplasmosis)) within 1 month or oral antibiotics within 2 weeks of study entry;
  • History of HIV or any opportunistic infection;
  • New York Heart Association Class III or IV heart failure;
  • Latent TB for which anti-tubercular treatment has not been started;
  • Untreated Hepatitis B or C infection;
  • History of deep venous thrombosis or pulmonary embolism; or
  • Pregnant or nursing women; or
  • History of herpes zoster or shingles in the previous 12 months and not subsequently vaccinated with herpes zoster vaccine.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Share:
Study Stats
Protocol No.
21-001683
Category
Autoimmune Disorders
Contact
Michelle Ramirez
Location
  • UCLA Alhambra
  • UCLA Arcadia
  • UCLA Beverly Hills
  • UCLA Burbank
  • UCLA Calabasas
  • UCLA Encino
  • UCLA Fountain Valley
  • UCLA Hollywood
  • UCLA Irvine
  • UCLA Laguna Hills
  • UCLA Marina del Rey
  • UCLA North Hollywood
  • UCLA Parkside
  • UCLA Pasadena
  • UCLA Porter Ranch
  • UCLA Redondo Beach
  • UCLA San Luis Obispo
  • UCLA Santa Barbara
  • UCLA Santa Clarita
  • UCLA Santa Monica
  • UCLA Simi Valley
  • UCLA Torrance
  • UCLA Ventura
  • UCLA Westlake Village
  • UCLA Westwood
  • UCLA Woodland Hills
For Providers
NCT No.
NCT04692493
For detailed technical eligibility, visit ClinicalTrials.gov.